The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Psychopharmacology, Journal Year: 2018, Volume and Issue: 235(7), P. 1923 - 1932

Published: April 4, 2018

Language: Английский

---

The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders

Current Neuropharmacology, Journal Year: 2019, Volume and Issue: 18(2), P. 87 - 96

Published: Sept. 4, 2019

Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood present with treatment-resistant forms of depression, co-morbid anxiety, other and bipolar disorders. Standardized essential oils (such as that Lavender officinalis) have been shown to exert clinical efficacy treating anxiety As endocannabinoids suggested play an important role major generalized disorders, Cannabis sativa was for their treatment. The endocannabinoid system is widely distributed throughout body including brain, modulating many functions. It involved related its activity may be modified by exogenous cannabinoids. CB1 CB2 receptors primarily serve binding sites well phytocannabinoids, produced cannabis inflorescences. However, ‘cannabis’ not a single compound product but known complicated molecular profile, producing plethora phytocannabinoids alongside vast array terpenes. Thus, “entourage effect” positive contribution derived addition terpenes Here, we review literature on effects cannabinoids discuss possibility enhancing cannabinoid symptoms terpenoids. Possible underlying mechanisms anti-depressant anxiolytic reviewed. These natural products potential source new medications treatment

Language: Английский

---

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2019, Volume and Issue: 269(1), P. 17 - 35

Published: Jan. 19, 2019

Language: Английский

---

THC and CBD: Similarities and differences between siblings

Neuron, Journal Year: 2023, Volume and Issue: 111(3), P. 302 - 327

Published: Jan. 12, 2023

---

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Frontiers in Pharmacology, Journal Year: 2018, Volume and Issue: 9

Published: May 11, 2018

Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress neurodegeneration. When available, the pharmacological therapies for these still mainly symptomatic, do not benefit all patients induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, neuroprotective Although studies investigate effects of this on movement surprisingly few, cannabidiol emerges promising treat and/or prevent them. Here, we review clinical pre-clinical draw attention potential in field.

Language: Английский

---

Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus

Neuropharmacology, Journal Year: 2018, Volume and Issue: 143, P. 163 - 175

Published: Sept. 28, 2018

Language: Английский

---

Opportunities for cannabis in supportive care in cancer

Therapeutic Advances in Medical Oncology, Journal Year: 2019, Volume and Issue: 11

Published: Jan. 1, 2019

Cannabis has the potential to modulate some of most common and debilitating symptoms cancer its treatments, including nausea vomiting, loss appetite, pain. However, dearth scientific evidence for effectiveness cannabis in treating these patients with poses a challenge clinicians discussing this option their patients. A review was performed using keywords related important treatments. Literature qualitatively reviewed from preclinical models clinical trials fields cancer, human immunodeficiency virus (HIV), multiple sclerosis, inflammatory bowel disease, post-traumatic stress disorder (PTSD), others, prudently inform use supportive palliative care cancer. There is reasonable amount consider pain as supplement first-line promising treat chemotherapy-induced peripheral neuropathy, gastrointestinal distress, sleep disorders, but literature thus far too limited recommend symptoms. Scant, yet more controversial, exists regard cancer- treatment-related cognitive impairment, anxiety, depression, fatigue. Adverse effects are documented tend be mild. multifaceted bioactive benefits that appear outweigh risks many situations. Further research required elucidate mechanisms action efficacy optimize preparations doses specific populations affected by

Language: Английский

---

Deconstructing the neurobiology of cannabis use disorder

Nature Neuroscience, Journal Year: 2020, Volume and Issue: 23(5), P. 600 - 610

Published: April 6, 2020

Language: Английский

---

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5251 - 5251

Published: March 9, 2023

Cannabis is the most used drug of abuse worldwide. It well established that abundant phytocannabinoids in this plant are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These two compounds have remarkably similar chemical structures yet vastly different effects brain. By binding to same receptors, THC psychoactive, while CBD has anxiolytic antipsychotic properties. Lately, a variety hemp-based products, including THC, become widely available food health industry, medical recreational use cannabis been legalized many states/countries. As result, people, youths, consuming because it considered “safe”. An extensive literature exists evaluating harmful both adults adolescents, but little known about long-term exposure, especially adolescence. The aim review collect preclinical clinical evidence cannabidiol.

Language: Английский

---

Novel rapid treatment options for adolescent depression

Pharmacological Research, Journal Year: 2024, Volume and Issue: 201, P. 107085 - 107085

Published: Feb. 2, 2024

There is an urgent need for novel fast-acting antidepressants adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of main research lines our group characterize at preclinical level approaches rapid-acting adolescence. The present review summarizes potential use in adolescence non-pharmacological options, such as neuromodulators (electroconvulsive therapy and other innovative types brain stimulation), well pharmacological including consciousness-altering drugs (mainly ketamine but also classical psychedelics) cannabinoids cannabidiol), with promising responses. Following a brief analytical explanation depression, we general introduction each therapeutical approach together clinical evidence supporting its beneficial extrapolated from prior successful examples adults), then report recent ongoing studies will aid improving inclusion these therapies clinic, by considering sex-, age-, dose-related differences, factors might affect efficacy long-term safety. Finally, conclude providing future avenues maximize treatment response, more importance designing testing options safe depression.

Language: Английский

---